Search

Smith & Nephew PLC

Slēgts

1,263 -1.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1258.5

Max

1280.5

Galvenie mērījumi

By Trading Economics

Ienākumi

296M

Pārdošana

3B

P/E

Sektora vidējais

30.104

22.135

EPS

0.429

Dividenžu ienesīgums

3

Peļņas marža

9.895

Darbinieki

17,000

EBITDA

723M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.25% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.00%

4.29%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.9B

12B

Iepriekšējā atvēršanas cena

1264.41

Iepriekšējā slēgšanas cena

1263

Smith & Nephew PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 13. nov. 21:34 UTC

Peļņas

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

2025. g. 13. nov. 23:45 UTC

Tirgus saruna

Nikkei May Fall After Wall Street's Weakness -- Market Talk

2025. g. 13. nov. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

2025. g. 13. nov. 23:41 UTC

Tirgus saruna

Gold Edges Higher on Possible Dip-Buying -- Market Talk

2025. g. 13. nov. 23:24 UTC

Peļņas

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

2025. g. 13. nov. 23:24 UTC

Peļņas

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

2025. g. 13. nov. 23:23 UTC

Peļņas

JBS NV 3Q EPS 52c >JBS

2025. g. 13. nov. 23:23 UTC

Peļņas

JBS NV 3Q Sales $22.6B >JBS

2025. g. 13. nov. 23:04 UTC

Tirgus saruna

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

2025. g. 13. nov. 22:02 UTC

Peļņas

Nu Holdings 3Q Net $783M >NU

2025. g. 13. nov. 22:01 UTC

Peļņas

Nu Holdings 3Q Rev $4.2B >NU

2025. g. 13. nov. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

2025. g. 13. nov. 21:50 UTC

Peļņas

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

2025. g. 13. nov. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

2025. g. 13. nov. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

2025. g. 13. nov. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

2025. g. 13. nov. 21:33 UTC

Tirgus saruna

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

2025. g. 13. nov. 21:33 UTC

Peļņas

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

2025. g. 13. nov. 21:31 UTC

Peļņas

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

2025. g. 13. nov. 21:25 UTC

Peļņas

Figure Tech Solutions 3Q Rev $156.4M >FIGR

2025. g. 13. nov. 21:25 UTC

Peļņas

Figure Tech Solutions 3Q EPS 34c >FIGR

2025. g. 13. nov. 21:23 UTC

Peļņas

Intchains Group 3Q Rev $1.3M >ICG

2025. g. 13. nov. 21:03 UTC

Peļņas

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

2025. g. 13. nov. 21:02 UTC

Peļņas

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

2025. g. 13. nov. 21:01 UTC

Peļņas

Applied Materials 4Q Rev $6.8B >AMAT

2025. g. 13. nov. 21:01 UTC

Peļņas

Applied Materials 4Q Gross Margin 48.0% >AMAT

Smith & Nephew PLC Prognoze

Cenas mērķis

By TipRanks

18.25% augšup

Prognoze 12 mēnešiem

Vidējais 1,516 GBX  18.25%

Augstākais 1,700 GBX

Zemākais 1,300 GBX

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat